◆ TICKERBASE · GLOBAL STOCK FINANCIAL DATA LIBRARY

Exelixis Inc (EXEL)

Name: Exelixis Inc（EXEL）— 財務諸表の推移
Creator: TickerBase
License: https://creativecommons.org/licenses/by/4.0/

公式財務諸表に基づく売上高、利益、キャッシュフローの推移。

HEALTHCARE · ウォール街（米国） · 最終更新: 2026-08-16

Exelixis, Inc., an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer. Its CABOMETYX and COMETRIQ are derived from cabozantinib, an inhibitor of multiple tyrosine kinases, including MET, AXL, RET, and VEGF receptors.

主要指標

時価総額: $13 billion
売上高（2025-12-31 期末の会計年度）: $2.3B
当期純利益: $783M
売上総利益率: 96.4%
純利益率: 33.7%

インタラクティブチャートと全財務諸表を見る → バリュエーションモデル（DCF）→

年次損益計算書

損益計算書	TTM → 2026-06-30	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31	2015-12-31	2014-12-31	2013-12-31	2012-12-31	2011-12-31	2010-12-31	2009-12-31	2008-12-31	2007-12-31	2006-12-31
売上高合計	$2.4B	$2.3B	$2.2B	$1.8B	$1.6B	$1.4B	$988M	$968M	$854M	$452M	$191M	$37M	$25M	$31M	$47M	$290M	$185M	$152M	$118M	$113M	$99M
売上総利益	$2.4B	$2.2B	$2.1B	$1.8B	$1.6B	$1.4B	$951M	$935M	$827M	$437M	$185M	$33M	$23M	$30M	$47M	$290M	$185M	$152M	$118M	$113M	$98M
売上総利益率 %	96.4%	96.4%	96.5%	96.0%	96.4%	96.3%	96.3%	96.6%	96.9%	96.7%	96.6%	89.5%	91.9%	96.4%	100.0%	100.0%	100.0%	100.0%	100.0%	99.8%	99.2%
営業利益（EBIT）	$971M	$872M	$605M	$171M	$201M	$287M	$110M	$369M	$439M	$166M	($28M)	($121M)	($224M)	($201M)	($122M)	$90M	($91M)	($122M)	($179M)	($157M)	($127M)
営業利益率 %	39.8%	37.6%	27.9%	9.3%	12.5%	20.0%	11.1%	38.2%	51.4%	36.7%	-14.7%	-326.7%	-893.9%	-640.5%	-258.0%	30.9%	-49.4%	-80.3%	-152.1%	-138.4%	-128.5%
当期純利益	$861M	$783M	$521M	$208M	$182M	$231M	$112M	$321M	$690M	$154M	($70M)	($170M)	($269M)	($245M)	($148M)	$76M	($92M)	($135M)	($163M)	($86M)	($101M)
純利益率 %	35.3%	33.7%	24.0%	11.3%	11.3%	16.1%	11.3%	33.2%	80.8%	34.1%	-36.7%	-456.6%	-1069.4%	-781.0%	-311.2%	26.1%	-49.9%	-89.1%	-138.2%	-76.1%	-102.9%
EBITDA	—	$922M	$719M	$283M	$222M	$300M	$119M	$378M	$452M	$167M	($22M)	($120M)	($213M)	($196M)	($115M)	$100M	($73M)	($116M)	($156M)	($157M)	($110M)
1株当たり利益（EPS）	$3.17	$2.78	$1.76	$0.65	$0.56	$0.72	$0.35	$1.02	$2.21	$0.49	$-0.28	$-0.81	$-1.38	$-1.33	$-0.92	$0.58	$-0.85	$-1.26	$-1.54	$-0.87	$-1.17
発行済株式数（百万株）	—	282M	296M	321M	325M	322M	318M	315M	313M	312M	251M	209M	194M	184M	160M	130M	109M	107M	105M	99M	87M

出典: 企業の公開資料（SEC）。数値をご利用の前に SEC EDGAR でご確認ください。

貸借対照表、キャッシュフロー計算書、四半期データおよび全財務比率は EXEL のインタラクティブ・ビューアーでご覧いただけます。 /companies/us/EXEL

類似企業

本サイトの情報は教育および情報提供のみを目的としており、投資助言ではありません。目標株価や投資判断は掲載していません。

English version →全銘柄

About TickerBase · Data methodology & sources · Privacy · Terms

TickerBase is provided for educational and informational purposes only. It does not constitute financial, investment, tax, or legal advice, or a recommendation to buy, sell, or hold any security. No price targets are published; any per-share value shown in the valuation workbench is generated entirely from reader-supplied assumptions and is not the publisher's view of fair value. Past performance does not predict future results. Figures are approximate and drawn from public filings; one-time items are noted where identified. Do your own research and consult a licensed professional before making any investment decision. The author may or may not hold positions in the securities discussed.